Preclinical Oncology Drug Intelligence - A Perfect Resource to Identify New Partners.

We are pleased to announce that Global Oncology Preclinical Drug Intelligence 2022 Report (11th Edition) is now available to its end users.

The Report is major update to its previous year edition and provides a complete detailed Insights on 1200 Active & well-funded Oncology Preclinical Stage Companies, developing over 1400+ New Drug Molecules.

KEY HIGHLIGHTS -

• Report covers Entrepreneurs established in last few years with valid funding and clear demarked pipeline with Individual’s Technology, Pipeline, Drug Targets, Management, Funding and Partnering capabilities.
• Complete Insights on Single Platform - Drug Developers, Emerging Technologies, Molecules, Targets, Mechanism of Action, Partnering Activities, Key Managements Social and Business Contacts.
• Best Selling Product since more than a decade, and is developed through years of continues & dedicated team work.
• Economic & User Friendly Option in compare with any other similar available market solution.
• Complete Free after sales Support and Further Report Customization Options with regular intelligence updates for next one year.

Specially designed to identify early stage researchers with new ideas capable of changing the face of drug discovery.

INSIDE REPORT - Complete Prebuild Intelligence (All in Single Report)

Small Molecule :?Kinase Inhibitors?(122 Preclinical Stage Companies).

Small Molecule :?Proteolysis Targeting Chimera (PROTACs)?(29 Preclinical Stage Companies).

Small Molecule :?RNA Targeting?Therapeutics?(43 Preclinical Stage Companies).

Nanoparticles / Nanotechnology?based Cancer Targeting Drugs?(61 Preclinical Stage Companies).

Cellular Therapy:?T Cell/CAR-T/CAR-NK & other Cell based Therapies?(125 Preclinical Stage Companies).

Oncolytic Viruses?Pipeline in Early Stage Development?(35 Preclinical Stage Companies).

Monoclonal Antibodies?Pipeline in Early Stage Development.?(162 Preclinical Stage Companies)

Bi-Specific & Multi Specific Antibodies?pipeline in Early Stage Development (66 Preclinical Stage Companies).

Antibody Drug Conjugates?Pipeline in Early Stage Development?(62 Preclinical Stage Companies).

Cancer Vaccines?Pipeline in Early Stage Development?(80 Preclinical Stage Companies)

Exosome & Microvesicles?based Cancer Targeting Drugs?(17 Preclinical Stage Companies).

Microbiome?based Cancer Targeting Drugs?(15 Preclinical Stage Companies).

Largest set of authentic early stage oncology drug developers worldwide with early stage molecules available for partnering and is a perfect tool to identify new partnering leads.

Further Details & Download Preview Copy :- https://omicsx.com/reports/cancer/global-oncology-preclinical-drug-intelligence-2022/

All Queries are welcome at : [email protected]